Poly(ADP-ribose) polymerase (PARP 4 ) catalyzes the formation of ADP-ribose polymers covalently attached to proteins by using NAD + as substrate. PARP is strongly activated by DNA single-or double-strand breaks and is thought to be involved in cellular responses to DNA damage. We characterized a dominant negative PARP mutant, i.e. the DNA-binding domain of this enzyme, whose overexpression in cells leads to increased genetic instability following DNA damage. In order to study whether PARP activity is also implicated in the process of tumorigenesis, we generated stably transfected HeLa cell clones with constitutive overexpression of dominant negative PARP and investigated tumor formation of these clones in nude mice. We found that inhibition of PARP activity dramatically reduces tumor forming ability of HeLa cells. Moreover, we provide strong evidence that the observed reduction in tumor forming ability is due to increased tumor cell apoptosis in vivo. Viewed together, our data and those from other groups show that inhibition of PARP enzyme activity interferes with DNA base excision repair and leads to increased genetic instability and recombination but, on the other hand, can sensitize cells to apoptotic stimuli and by this mechanism may prevent tumor formation.
Introduction
Poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) catalyzes the transfer of ADP-ribose moieties derived from NAD + to various acceptor proteins including PARP itself. This poly(ADP-ribosyl)ation of proteins is drastically stimulated upon binding of the PARP DNA-binding domain (DBD) to single-or doublestrand breaks of DNA (Lindahl et al., 1995) . Although precise functions and molecular mechanisms of poly(ADP-ribosyl)ation are still not clear, it is generally accepted that PARP plays an active role in the cellular recovery from DNA damage. Furthermore, it has been described that PARP is quantitatively cleaved during Fas ligand-or DNA damage-induced apoptosis by caspase-3 (Tewari et al., 1995; Nicholson et al., 1995) . In order to investigate PARP functions, we had developed the stably transfected CO60 hamster subline COM3, in which inhibition of poly(ADPribosyl)ation is achieved by dexamethasone-inducible overexpression of the mere DBD of PARP, acting as a dominant negative mutant of this enzyme. Most likely, dominant negative PARP competes with resident fulllength PARP for DNA strand breaks and by this it inhibits the DNA damage-induced formation of poly(ADP-ribose). We could show that this way of PARP inhibition sensitizes cells to genotoxic stress and potentiates carcinogen-induced genetic instability (KuÈ pper et al., 1995 . Here we developed HeLa transfectants with constitutive overexpression of the dominant negative PARP mutant. We observed a greatly reduced tumor forming ability of these transfectants in nude mice and found evidence for increased tumor cell apoptosis in vivo.
Results

Generation of HeLa cell transfectants with constitutive overexpression of the PARP DBD
Based on the SV40-transformed hamster cell line CO60 we have previously established a stably transfected cell culture system with dexamethasone-inducible overexpression of the DBD of human PARP, causing trans-dominant inhibition of poly(ADP-ribosyl)ation. In these so-called COM3 cells, we could show that expression of dominant negative PARP sensitizes cells against g-irradiation and the alkylating agent MNNG, while there was neither an in¯uence detectable on DNA replication nor on cellular proliferation in the absence of genotoxic stress (KuÈ pper et al., 1995) . This sensitization is associated with a block in DNA base excision repair (Molinete et al., 1993) and increased gene ampli®cation and sister chromatid exchanges (KuÈ pper et al., 1995 Schreiber et al., 1995) . We were then interested to see whether PARP DBD overexpression aects tumor formation in nude mice. Since CO60 hamster cells do not form tumors in nude mice despite expression of SV40 large T-antigen (J-H KuÈ pper, unpublished data), we generated transfectants of the human cervical carcinoma cell line HeLa. Based on plasmid pPARP6 (KuÈ pper et al., 1990 ) that contains the cDNA of the human PARP DBD under the control of the human cytomegalovirus promoter, we established two sets of HeLa cell clones: The one set, represented by the clones HEC1 ± HEC4, were cultured for more than one year before analysis of tumor formation. The other set is represented by the clones HEC7 and HEC12 that were established only two months before the start of animal experiments. All of these clones show strong expression of the DBD in Western blots (Figure 1 ) in contrast to control clones HEN1 ± HEN4 that were generated by vector transfection of HeLa cells. In order to see whether constitutive DBD expression in HEC transfectants causes the same inhibition of poly(ADP-ribosyl)ation as we had demonstrated for our inducible hamster cell lines, we performed immuno¯uorescence analyses of poly(ADPribose) formation after high-dose g-irradiation. This is shown for clone HEC7, serving as a representative example, in Figure 2 . The ®gure clearly demonstrates exogenous DBD overexpression throughout the HEC7 cell population, while the endogenous DBD as an integral part of PARP protein is not detectable under these conditions in parental HeLa cells. Treatment of cells with 56 Gy g-irradiation leads to massive DNA damage which normally stimulates PARP drastically to synthesize poly (ADP-ribose). This is the case in untransfected HeLa cells, while there is ecient inhibition of poly(ADP-ribosyl)ation in g-irradiated HEC7 cells (Figure 2 ), as expected. Both cell lines were negative for poly(ADPribose) immunostaining in the absence of DNA damage (data not shown). Trans-dominant inhibition of poly(ADP-ribosyl)ation could also be observed in DBDoverexpressing cells of the other HEC transfectants, while non-expressing cells of HEC clones (see below) didn't show PARP inhibition as expected. All HEN transfectants behave like parental HeLa cells (data not shown).
HeLa clones overexpressing the DBD have reduced ability to form tumors
In order to analyse the tumorigenicity of the HeLa transfectants obtained, we injected HEC, HEN, or parental HeLa cells subcutaneously into the¯anks of nude mice. This was ®rst done with clones HEC1 ± 4 that had already been maintained in culture for one year. The results are given in Table 1A . As expected, parental HeLa cells and both HEN transfectants tested developed tumors in all experiments. Surprisingly, we observed a dramatic reduction of tumorigenicity in clones overexpressing the DBD: Clones HEC2 and HEC4 displayed a clearly reduced tumor-forming ability while clones HEC1 and HEC3 never formed tumors. Interestingly, the dierences in tumor-forming ability between these four HEC clones correlated with dierences in the fraction of cells expressing the DBD as visualized by immuno¯uorescence. Those clones with a total lack of tumor-forming ability expressed the DBD in a much higher fraction of cells than the clones with only reduced tumor formation (Table 1A) . In order to further analyse this unexpected result, we proceeded with animal experiments, testing the second set of clones, HEC7 and HEC12, that were established shortly before. Although these two clones expressed the dominant negative PARP quite homogenously, no tumor-reducing eect of the transgene was visible at the same high tumor cell inoculum size that was used for HEC1 ± HEC4. However, when a middle inoculum size was injected, a clear-cut reduction of tumorforming ability was apparent compared to vectortransfected control clones or parental HeLa cells (Table 1B) . Moreover, both control clones tested were also tumorigenic at an even smaller inoculum size (data not shown). We routinely measured tumor growth rates once a week, but there were no dierences detectable between HeLa, HEN and HEC tumors. In vitro growth rates of cell lines were not comparable either. Figure 1 Western blot analysis of DBD overexpression in HEC cell cultures. Crude protein extracts from 10 5 cells were loaded and subjected to SDS ± PAGE and immunoblotting. Blots were developed with antibody C-II-10 and ECL as described in Materials and methods Figure 2 Immuno¯uorescence analysis of DBD overexpression and poly(ADP-ribose) formation in HEC7 and HeLa cells. HeLa or HEC7 cells were ®xed with formaldehyde, and immunofluorescence analysis was done by using monoclonal antibody F-I-23 to detect DBD expression, as indicated. In order to investigate poly(ADP-ribose) formation, cells were subjected to 56 Gy girradiation as described in Materials and methods. Cells were ®xed with trichloroacetic acid and immuno¯uorescence analysis was performed by using monoclonal antibody 10H as indicated. Secondary antibodies were FITC-labeled
Evidence for increased tumor cell apoptosis in vivo by PARP inhibition
In order to see whether dierences in the tumorforming ability of HEC clones were due to dierent levels of DBD expression after tumor cell inoculation, we performed Western blot analyses of tumor extracts. The most likely explanation for this observation is that HEC tumors contain apoptotic cells. It is well known that PARP is quantitatively cleaved within its bipartite nuclear localization signal by caspase-3 during apoptosis, giving rise to a 25K amino-terminal fragment, comprising most of the DBD, and a 88K carboxy-terminal fragment that can be detected with monoclonal antibody C-II-10 ( Kaufmann et al., 1993; Nicholson et al., 1995; Tewari et al., 1995) . A protein fragment of the latter size is clearly detectable in blots from HEC tumors. If apoptosis occurs in tumors expressing the DBD, there should be a small protein fragment detectable by monclonal antibody C-II-10 that spans the region from the caspase-3 cleavage site at aminoacid position 216 up to the end of the exogenous DBD at aminoacid position 372. This fragment should have a size of about 20K. Indeed, a small protein fragment of this size is clearly visible in blots from HEC tumors, while it is absent in routine cultures of the same transfectants and in a cell culture derived from a HEC12 tumor (Figure 3a) . Strong evidence that this 20K fragment of HEC tumors was generated during apoptosis comes from experiments with our previously characterized COM3 hamster cells: While such a fragment is also normally absent in dexamethasone-treated cultures of COM3 cells ( Figure  3b /I, 7MNNG/+DEX), we do detect this small fragment in blots from dexamethasone-induced COM3 cultures 24 h after treatment with the alkylating agent MNNG (Figure 3b , +MNNG/+DEX). Under these conditions a large fraction of COM3 cells undergo apoptosis as analysed by DAPI staining of nuclei ( Figure 3c ) and DNA fragmentation assays (data not shown), while MNNG-treated COM3 cells without expression of the DBD showed the apoptotic phenotype much less frequently. Moreover, when we analysed cell debris from the supernatants of MNNGtreated cultures, we found quantitative cleavage of the 46 K DBD (Figure 3b /II, +MNNG/+DEX), demonstrating that these cells were killed by apoptosis. In order to further analyse apoptosis in HEC tumors, we investigated expression of the protein Bax. Bax is a proapoptotic member of the Bcl-2 family, and it is thought that a pre-set ratio of Bcl-2/Bax determines the survival or death of cells following an apoptotic stimulus (reviewed in: Korsmeyer, 1995) . The Western blot in Figure 4 clearly shows that tumors from the three HEC clones contain increased levels of Bax compared to the HeLa tumor and to cell cultures from the same lines. This strongly favors the hypothesis that there is increased incidence of apoptosis in HEC tumors.
Discussion
The objective of this study was to investigate a possible in¯uence of PARP activity on the process of tumorigenesis. Since PARP has been postulated to play a positive role in the maintenance of genomic stability, we expected that functional expression of a dominant negative PARP, i.e. the DBD of this enzyme, would increase the potential of an established cancer cell line to form tumors in a nude mouse model. However, the results we obtained were opposite to that what we expected. Since we observed a clearly reduced tumor formation in two sets of HeLa transfectants that were generated independently, the observed fundamental dierences between HEC and HEN clones cannot be explained by clonal variation. One explanation for these unexpected results could be that DBD expression abrogates the transformed status of HeLa cells, rendering them unable to form tumors in nude mice. If this assumption is correct, tumors obtained from HEC transfectants should be the result of an in vivo selection against DBD expression, so that This mechanism should be more likely to occur in those transfectants where the PARP DBD is not stably overexpressed throughout the cell population, i.e., in clones with heterogeneous transgene expression or in unstable clones that had been in culture for only a short period of time. Indeed Table 1 documents heterogeneous expression in clones HEC2 and HEC4, while all the other HEC clones displayed a quite homogeneous expression pattern of the DBD. Thus, selection against DBD expression might occur in HEC2 and HEC4 and also in those transfectants that had been in culture for only two months (HEC7 and HEC12) and in which therefore stable integration might not have been occurred yet. However, the Western blot in Figure 3a demonstrates that there is in fact ongoing expression of the DBD in tumors derived from HEC2, HEC7 and HEC12 cells. From this observation we conclude that DBD-expressing HeLa cells are still transformed.
At this time, we do not know exactly why the second set of HEC transfectants (HEC7 and HEC12) exhibits reduced tumor formation only at a lower tumor cell inoculum size, in contrast to those clones that had been in culture for a much longer period (HEC1 ± HEC4). We hypothesize that this could be due to genetic dierences accumulating over time in clones that constitutively express the dominant negative PARP. In any case, we provide strong evidence that the reduced tumor-forming ability of HEC clones is due to sensitization for apoptosis in both sets of clones. It is well known that PARP and other DNA repairassociated enzymes like DNA-dependent protein kinase are cleaved by caspase-3 during apoptosis (Nicholson et al., 1995; Tewari et al., 1995; Teraoka et al., 1996; Song et al., 1996) . It is possible that this PARP cleavage, rather than the presence of PARP itself, is important for some apoptotic programs, since thymocytes from PARP 7/7 mice exhibit normal apoptotic responses after a variety of stimuli (Wang et al., 1997) , in contrast to PARP 7/7 cells that were transfected with an uncleavable PARP mutant (Oliver et al., 1998) . These results are in con¯ict with the ®nding that depletion of PARP by antisense RNA and absence of the early burst of poly(ADP-ribosyl)ation that normally occurs prior to PARP cleavage interferes with anti-Fas and cycloheximide-induced apoptosis (Simbulan et al., 1998) . Taking together these experimental results, it is hard to speculate at present which function(s) of PARP are necessary for or can interfere with apoptosis. We hold the view that It is conceivable that a dominant negative PARP sticks to DNA breaks like wild-type PARP is supposed to do, when it is unable to perform automodi®cation with poly(ADP-ribose) due to NAD + de®ciency or presence of chemical inhibitors blocking the catalytical center of this enzyme (Satoh et al., 1993) . But it is also possible that catalytically inactive PARP molecules or DBD molecules are displaced from the strand breaks by e.g. repair proteins and the biological eects observed are solely due to the absence of poly(ADP-ribosyl)ation. By contrast, knocking out PARP either by homologous recombination or by expressing PARP antisense RNA interferes with any function of PARP protein, including poly(ADP-ribosyl)ation, binding to DNA strand breaks and, as shown recently, in¯uences on transcription (Oei et al., 1998; Butler and Ordahl, 1999) . Thus it is conceivable that, if PARP has several functions, a complete loss of all of these functions due to gene targeting or antisense technology can result in a dierent phenotype than loss of only one function such as catalytic activity. Our results, showing that the absence of polymer production by expression of dominant negative PARP increases DNA damageinduced apoptosis, favor the hypothesis that poly(ADP-ribosyl)ation is a negative regulator of this form of apoptosis. Our results are in line with published work showing that there is increased MNNG-induced apoptosis in stably transfected HeLa cell cultures expressing the PARP DBD (Schreiber et al., 1995) . It is not yet clear by which mechanism the DBD facilitates apoptosis in vivo, but it is obvious to speculate that this eect is due to increased sensitivity to oxidative stress caused by the attack of immunocompetent cells other than T-cells.
In conclusion, there is much information showing that abrogation of PARP activity can interfere with DNA base excision repair, leading to increased genetic instability and recombination (Jeggo, 1998) , but, on the other hand, it can also sensitize cells to apoptotic stimuli and by this mechanism may prevent tumor formation. We are currently investigating the mechanisms that are responsible for the increased tumor cell apoptosis. In any event, the results of this study should be relevant for current approaches towards innovative cancer therapy, because the targeting of apoptotic pathways by gene therapeutic or pharmacologic strategies is believed to be a very promising option for the treatment of cancer.
Materials and methods
Antibodies and plasmids
Monoclonal antibodies C-II-10 ( Lamarre et al., 1988) and F-I-23 (van Gool et al., 1997) directed against the PARP DBD were kindly provided by GG Poirier, QueÂ bec, Canada. Mouse monoclonal antibody 10H (Kawamitsu et al., 1983) against poly(ADP-ribose) was kindly provided by M Miwa and T Sugimura, Tokyo, Japan. Monoclonal antibody 6A7 against Bax was from Pharmingen, Hamburg, Germany. Peroxidase-conjugated rabbit anti-mouse immunoglobulins were from Dianova, Hamburg, Germany. FITC-conjugated goat anti-mouse immunoglobulins were from Renner, Darmstadt, Germany. Plasmid pTKneo was kindly provided by M Boshart, MuÈ nchen, Germany.
Cell culture
HeLa cells were maintained as monolayers as described . To obtain stably transfected cell clones, HeLa cultures were transfected with plasmid pPARP6 (KuÈ pper et al., 1990) together with pTKneo using the calcium phosphate transfection protocol. For the generation of control clones, HeLa cultures were transfected with vector pL15TK (KuÈ pper et al., 1990) together with pTKneo. Cells were selected with 1000 mg/ml geneticin (GIBCO, Karlsruhe, Germany), and DBD-expressing clones were identi®ed by Western blotting and immuno¯uorescence. Selected clones were further subcloned by endpoint dilution, giving rise to HEC1-12 clones, i.e. clones that express the DBD, and HEN1-4 control clones, respectively. Selection media were replaced with routine medium one day prior to experimental manipulations. COM3 hamster cells were propagated as described (KuÈ pper et al., 1995) . In order to induce DBD overexpression, COM3 cells were treated with 5610 78 M dexamethasone (Sigma, Deisenhofen, Germany) for 24 h. To trigger apoptosis, cells were exposed to 100 mM N-methyl-N'-nitro-N-nitrosoguanidine (MNNG, Sigma). One day later, cells were harvested for Western blotting (see below) or were ®xed with methanol and stained with DAPI (Boehringer, Mannheim, Germany) according to the protocol provided by the manufacturer.
Western blot
Crude protein extracts from cell cultures were prepared as described (KuÈ pper et al., 1995) . Protein extracts from tumor samples were prepared as will be described in detail elsewhere (J-H KuÈ pper, manuscript in preparation). Brie¯y, frozen tumor samples were mechanically crushed by using a small steel ball and a cell disrupter (MiniBeadbeater-8, Biospec Products, Bartlesville, OK, USA). Tumor material was denatured for 5 min at 958C in 58.8 mM Tris-HCl buer, pH 6.7, supplemented with 1% SDS and protease inhibitors. Protein concentrations were determined by the method of Whitaker and Granum (1980) . Thereafter, an equal volume of 58.8 mM Tris-HCl, 1% SDS, 2% 2-mercaptoethanol, and 20% glycerol was added to the protein samples, followed by an additional denaturation of proteins at 958C for 2 min. After separation by 10% SDS ± PAGE, proteins were electroblotted onto Immobilone-P membranes (Millipore, Eschborn, Germany). Blots were developed by using monoclonal antibody C-II-10 or 6A7 in combination with ECL (Amersham, Braunschweig, Germany).
Indirect immuno¯uorescence
Immuno¯uorescence detection of overexpressed`transgene' and of poly(ADP-ribose) formation, respectively, was performed exactly as described previously (van Gool et al., 1997) . Brie¯y, DBD expression was analysed in formaldehyde-®xed cells by using monoclonal antibody F-I-23 and FITC-conjugated secondary antibodies. To analyse poly(ADP-ribose) formation, cells grown on coverslips were subjected to 56 Gy g-irradiation as described (KuÈ pper et al., 1990) . Poly(ADP-ribose) was detected by monoclonal antibody 10H and FITC-conjugated secondary antibodies.
Animal experiments
Exponentially growing HeLa cells and transfectants derived thereof were trypsinized, washed once, and resuspended in PBS. Cell suspensions were injected subcutaneously at densities between 2.5610 5 and 2610 6 cells/100 ml into thē anks of six-week-old athymic Swiss CD1-nu/nu mice (Ia Credo, L'Arbresle, France). Three to four weeks after tumor cell inoculation, mice were sacri®ced, and tumor samples were frozen in liquid nitrogen. In some experiments tumor material was cut into small pieces and trypsinized, and tumor cells were further incubated under routine conditions at 378C and 5% CO 2 .
Abbreviations DBD, DNA-binding domain of PARP; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine; PARP, poly(ADP-ribose) polymerase; SV40, simian virus 40.
